Bioretec Q2 EBITDA loss narrows to EUR 2.25 million; net sales rise 62.2% to EUR 1.1 million

• Bioretec posted Q2 net sales of EUR 1.1 million, up 62.2% year over year.
• EBITDA loss narrowed to EUR 2.25 million; net loss improved to EUR 3.31 million.
• H1 net sales rose 11.9% to EUR 2.32 million; EBITDA loss narrowed to EUR 3.63 million.
• H1 net loss improved to EUR 4.68 million; cash and cash equivalents totaled EUR 12.02 million.
• CEO cited continued commercial momentum, with Q2 net sales up 133.6% in the U.S. and 63.9% in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioretec Oyj published the original content used to generate this news brief via Cision (Ref. ID: 20260812:BIT:6983:0) on August 13, 2026, and is solely responsible for the information contained therein.